Hepatitis B vaccine

United States Court Admits Hepatitis B Vaccine Caused Fatal Autoimmune Disease In Infant .

Posted by

1


In our society today, newborns are injected with loads of chemicals nearly as soon as they enter the world. In the name of “prevention”, we give them vaccines that we aren’t even sure are safe. As a matter of fact, in many cases, we know them to be unsafe. This is the case with the hepatitis B vaccine, approved for infants at birth but admittedly responsible for causing serious illness and even death. The United States Court of Federal Claims sided with the estate of Tambra Harris, who died as a result of an auto-immune disease called systemic lupus erythematosus (SLE). The court awarded $475,000 following her death after finding the hepatitis vaccine caused her injury in the form of SLE. But this near-admittance of a cause-effect relationship between the vaccine and the illness and subsequent death isn’t enough. No, we still give the shot to babies.

So, what is hepatitis B and why are we told that it is so important that newborn infants are vaccinated against it? Hepatitis B is not pleasant and can be deadly. But newborns (and the vast majority of people at any age) aren’t at risk of contracting the disease. It’s spread by contact with bodily fluids, as in through unprotected sex or dirty needles.

The risks associated with the hepatitis B vaccine are far more pressing than the risk of contracting the disease, says Dr. Jane Orient of the Association of American Physicians and Surgeons (AAPS). “For most children, the risk of a serious vaccine reaction may be 100 times greater than the risk of hepatitis B.”

Still, newborns are given the vaccine within moments of entering the world.

Considered by many to be crimes against infants, the hep-b vaccination, the vaccine has been linked to sudden infant death syndrome (SIDS), multiple sclerosis, and other autoimmune disorders. Many experts have questioned the prolific use of the vaccine since it stepped on the scene a few decades ago. What’s more, many parents are starting to question the need for the vaccine.

“In increasing numbers, parents across the country are contacting the National Vaccine Information Center (NVIC) to report opposition to regulations being enacted by state health department officials that legally require children to be injected with three doses of hepatitis B vaccine before being allowed to attend daycare, kindergarten, elementary school, high school or college,” National Vaccine Information Center reads.

As a parent, it is still your decision whether or not to vaccinate your child. There is plenty of research out there to help guide you in this decision. Don’t let your doctor or the people around you be your only source of information. Do your research and determine the best solution for your child’s long-term health.

Antiviral Therapy Safely Stopped in HBeAg-Negative Patients with Hepatitis B Infection.

Posted by

0


Discontinuing adefovir did not lead to any adverse events during 5.5 years of follow-up.

Although oral antiviral agents are effective in suppressing hepatitis B virus (HBV) in hepatitis B e antigen (HBeAg)-negative patients, it is unclear if therapy can ever be stopped. Previous studies observed that viral relapse occurred universally after a short course of treatment (J Gastroenterol Hepatol 2011; 26:456). Long-term suppressive therapy may afford an opportunity to eventually stop treatment.

In this observational study, a group of 33 well-characterized HBeAg-negative patients with HBV infection who had been receiving suppressive therapy with adefovir (10 mg daily) for 4 to 5 years discontinued treatment. Patients were then followed for 5.5 years, with measurement of serum alanine aminotransferase (ALT), hepatitis B surface antigen (HBsAg), and HBV DNA every 3 to 6 months to assess for relapse of HBV infection.

During a median follow-up of 69 months, 18 of 33 patients (55%) maintained persistently normal ALT and undetectable viral load (HBV DNA <29 IU/mL). Of these 18 responders, 13 (72%) cleared HBsAg, and 9 of the 13 (69%) seroconverted to hepatitis B surface antibody (HBsAb). No adverse events occurred, and in the 45% of patients who relapsed, an oral antiviral agent was safely restarted.

Comment: This long-term, prospective cohort study of a small group of HBeAg-negative patients with hepatitis B infection suggests that patients whose viral loads are suppressed with an oral agent for 4 to 5 years can safely discontinue antiviral therapy. Moreover, about half will not experience viral relapse, and the majority of these patients will develop HBsAb. However, stopping therapy should be considered only in highly compliant patients without cirrhosis. In patients with cirrhosis, close monitoring is necessary, and viral relapse can lead to hepatic decompensation.

Souurce: Journal Watch Gastroenterology